文献速递乳腺癌支持与姑息治疗

比较依那普利两种预防策略指导蒽环类心脏毒性的多中心随机试验

Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial.
PubMed 文献 · Eur J Cancer · 2018-03-20

ICOS-ONE 试验在 21 家意大利医院随机比较两种依那普利策略:全部患者化疗前开始用药的「预防」策略,与仅肌钙蛋白升高后开始用药的「肌钙蛋白触发」策略。273 例患者中肌钙蛋白升高发生率分别为 23% 与 26%(p=0.50),心脏毒性仅 3 例(1.1%)。低累积剂量蒽环类且低心血管风险患者中两策略无差异。

要点

  • 低累积剂量蒽环类且低心血管风险患者肌钙蛋白升高率两策略无差异(23% vs 26%,p=0.50)。
  • 心脏毒性(LVEF 降低 10 个百分点且低于 50%)仅 3 例(1.1%),两策略间无明显差异。
  • 考虑到依那普利预防 LV 功能障碍的获益,肌钙蛋白触发策略可能更便利。

核心结论

  • 低累积剂量蒽环类且低心血管风险成人患者中,两种依那普利给药策略的肌钙蛋白升高发生率无差异(23% vs 26%,p=0.50)。
  • 心脏毒性发生率低(3 例,1.1%),两策略间无明显差异。
  • 考虑依那普利预防 LV 功能障碍的获益,肌钙蛋白触发策略可能更便利。

研究设计与样本

  • ICOS-ONE 为在 21 家意大利医院开展的对照、开放标签试验。
  • 273 例患者随机分配至预防策略(全部患者化疗前开始依那普利)或肌钙蛋白触发策略(仅肌钙蛋白升高后开始依那普利)。
  • 肌钙蛋白在 2596 份血样中本地检测,于每个蒽环类化疗周期前后及每次研究访视时采集;心电图和超声心动图于基线及 1、3、6、12 个月随访时进行。
  • 主要结局为肌钙蛋白升高超过阈值的发生率。

主要发现

  • 273 例患者中 88% 为女性,平均年龄 51 ± 12 岁。
  • 76% 为乳腺癌,3% 有高血压史,4% 有糖尿病。
  • 最常用蒽环类为表柔比星和 doxorubicin(多柔比星),中位累积剂量分别为 360 [270-360] mg/m2 和 240 [240-240] mg/m2。
  • 肌钙蛋白升高发生率在预防组为 23%,肌钙蛋白触发组为 26%(p=0.50)。
  • 3 例患者(1.1%)发生心脏毒性(定义为 LVEF 降低 10 个百分点且值低于 50%),预防组 2 例,肌钙蛋白触发组 1 例。

关键数值与推荐

  • 心脏毒性定义为 LVEF 降低 10 个百分点且 LVEF 值低于 50%。
  • 主要结局为肌钙蛋白升高超过阈值,阈值原文未具体报告。

临床怎么用

  • 对于接受低累积剂量蒽环类且心血管风险低的成人患者,可考虑采用肌钙蛋白触发策略使用依那普利,以避免全部患者预防性用药。
  • 需按方案监测肌钙蛋白、心电图和超声心动图(基线及 1、3、6、12 个月)。

局限性

  • 原文摘要未报告盲法实施细节及样本量计算依据。
  • 心脏毒性事件数少(3 例),限制两策略在心脏毒性终点的比较。
  • 肌钙蛋白阈值及检测方法细节在摘要中未具体说明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Troponin changes over time have been suggested to allow for an early diagnosis of cardiac injury ensuing cancer chemotherapy; cancer patients with troponin elevation may benefit of therapy with enalapril. It is unknown whether a preventive treatment with enalapril may further increase the benefit. METHODS: The International CardioOncology Society-one trial (ICOS-ONE) was a controlled, open-label trial conducted in 21 Italian hospitals. Patients were randomly assigned to two strategies: enalapril in all patients started before chemotherapy (CT; 'prevention' arm), and enalapril started only in patients with an increase in troponin during or after CT ('troponin-triggered' arm). Troponin was assayed locally in 2596 blood samples, before and after each anthracycline-containing CT cycle and at each study visit; electrocardiogram and echocardiogram were done at baseline, and at 1, 3, 6 and 12-month follow-up. Primary outcome was the incidence of troponin elevation above the threshold. FINDINGS: Of the 273 patients, 88% were women, mean age 51 ± 12 years. The majority (76%) had breast cancer, 3% had a history of hypertension and 4% were diabetic. Epirubicin and doxorubicin were most commonly prescribed, with median cumulative doses of 360 [270-360] and 240 [240-240] mg/m2, respectively. The incidence of troponin elevation was 23% in the prevention and 26% in the troponin-triggered group (p = 0.50). Three patients (1.1%) -two in the prevention, one in the troponin-triggered group-developed cardiotoxicity, defined as 10% point reduction of LV ejection fraction, with values lower than 50%. INTERPRETATION: Low cumulative doses of anthracyclines in adult patients with low cardiovascular risk can raise troponins, without differences between the two strategies of giving enalapril. Considering a benefit of enalapril in the prevention of LV dysfunction, a troponin-triggered strategy may be more convenient.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Cardinale D, Ciceri F, Latini R, et al. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. Eur J Cancer. 2018. PMID: 29567630. doi:10.1016/j.ejca.2018.02.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。